Showing results (81-90 of 226) with videos related to

Sort By:
Pageof 23
Human Mutation|January 12, 2008
Sedoheptulokinase deficiency due to a 57-kb deletion in cystinosis patients causes urinary accumulation of sedoheptulose: elucidation of the CARKL geneMirjam M C Wamelink, Eduard A Struys, Erwin E W Jansen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 12, 2025
Summary Report of the SNMMI AI Task Force Radiomics Challenge 2024Ronald Boellaard, Arman Rahmim, Jacoba J Eertink, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 24, 2025
Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long-Axial-Field-of-View PET/CT SystemCharlotte L C Smith, Gerben J C Zwezerijnen, Marijke E den Hollander, et al.
Scientific Reports|February 26, 2023
Immune activation of vaginal human Langerhans cells increases susceptibility to HIV-1 infectionNienke H van Teijlingen, Julia Eder, Ramin Sarrami-Forooshani, et al.
EJNMMI Research|January 9, 2014
18 F-fluorothymidine uptake in follicular lymphoma and error-prone DNA repairMarielle J Wondergem, Ken Herrmann, Sergei Syrbu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 25, 2018
Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysisCoreline N Burggraaff, Antoinette de Jong, Otto S Hoekstra, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2021
Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?Jakoba J Eertink, Elisabeth A G Pfaehler, Sanne E Wiegers, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 13, 2006
Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomographyLars R Perk, Otto J Visser, M Stigter-van Walsum, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 6, 2012
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PETSaiyada N F Rizvi, Otto J Visser, Maria J W D Vosjan, et al.
EJNMMI Research|August 21, 2021
Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an exampleMarc C Huisman, C Willemien Menke-van der Houven van Oordt, Josée M Zijlstra, et al.
Pageof 23